Section Arrow
Quote
ADRX.NASDAQ
- ADARx Pharmaceuticals Inc.
Quotes are at least 15-min delayed:2026/11/09 15:28 EST
Regular Hours
Last
 13.83
+0.6 (+4.54%)
Day High 
13.9944 
Prev. Close
13.23 
1-M High
19.0688 
Volume 
266.67K 
Bid
13.7
Ask
13.96
Day Low
12.7 
Open
13.24 
1-M Low
12.5 
Market Cap 
1.41B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 16.21 
20-SMA 16.93 
50-SMA -- 
52-W High 23.21 
52-W Low 12.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.82/--
Enterprise Value
1.42B
Balance Sheet
Book Value Per Share
-2.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.45M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
EDSAEdesa Biotech2.5451+0.4051+18.93%-- 
ZURAZura Bio Limited1.165-2.925-71.52%-- 
HRTXHeron Therapeutics0.38135+0.08835+30.15%-- 
IBRXImmunityBio7.285-1.35-15.63%-- 
INOInovio Pharmaceuticals1.505+0.29+23.87%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.